Greece: A large-scale study evaluating brodalumab for moderate-to-severe plaque psoriasis revealed significant improvements in patient outcomes.

The study of 638 patients showed that brodalumab led to substantial reductions in the Psoriasis Area and Severity Index (PASI) scores, with 74.0% achieving PASI ≤3 by week 12. In particular, 54.1% of patients achieved complete clearance (PGA0). The findings were published online in the Journal of the European Academy of Dermatology and Venereology on February 03, 2024.

In the psoriasis treatment landscape, it is crucial to understand the real-world effectiveness of medications for healthcare professionals to make informed decisions. The BrIDGE study in Greece offers valuable insights into brodalumab effectiveness in patients with moderate-to-severe plaque psoriasis.
Brodalumab, a human monoclonal antibody targeting the interleukin-17 receptor, has shown promising results in clinical trials for treating psoriasis. However, real-world data is essential to confirm its efficacy and safety in diverse patient populations. Therefore, Dimitrios Rigopoulos, 1st Department of Dermatology-Venereology, University of Athens, Athens, Greece, and colleagues conducted an observational, prospective, single-cohort, multicentre study (BrIDGE) that recruited patients with moderate-to-severe plaque psoriasis in Greece.
The primary objective was to assess the proportion of patients who achieved PASI 100 after 24 weeks. Other endpoints included: the short-term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12–16 weeks, the maintenance of PASI90/100 through to 104 weeks, and the time to complete clearance. Moreover, the researchers explored the change in the quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.
The researchers recruited two hundred patients initiating treatment with or switching to brodalumab. Analyses were conducted using the observed data and three imputation approaches were applied for the missing data.
The study led to the following findings:
Based on the ‘as observed data’, 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104.
In total, 70.2%, 47.5%, and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12–16.
For sPGA status 82.8%, 89.2%, and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52, and 104, respectively.
The time to achieve PASI100 at Weeks 12–16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104.
Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Treatment adherence was equal to 98.9%.
In conclusion, the study found that brodalumab confers rapid and durable responses and improvements in the quality of life of patients with moderate-to-severe psoriasis.
Reference:
Rigopoulos, D., Tampouratzi, E., Angelakopoulos, C., Apalla, Z., Barkis, I., Georgiou, S., Delli, F., Drosos, A., Zafiriou, E., Katsantonis, J., Lazaridou, E., Panagakis, P., Papadavid, E., Papakonstantis, M., Roussaki-Schulze, V., Sotiriou, E., Anastasiadis, G., Chasapi, V., Sfaelos, K., . . . Ioannides, D. Real-world data on the effectiveness of brodalumab in patients with moderate-to-severe plaque psoriasis in the Greek clinical setting (the BrIDGE study). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19816